Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Rezolute (NASDAQ:RZLTGet Free Report) announced its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Stock Up 5.4 %

Rezolute stock opened at $5.08 on Friday. Rezolute has a 52-week low of $0.72 and a 52-week high of $6.10. The firm has a market capitalization of $203.89 million, a price-to-earnings ratio of -4.46 and a beta of 1.18. The firm has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $3.72.

Analyst Ratings Changes

Several equities research analysts have issued reports on RZLT shares. Guggenheim assumed coverage on Rezolute in a report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a research note on Friday. Maxim Group raised their price objective on shares of Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 6th. Craig Hallum began coverage on shares of Rezolute in a research note on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $11.57.

Read Our Latest Analysis on RZLT

About Rezolute

(Get Free Report)

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Featured Stories

Earnings History for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.